Vertex Pharmaceuticals Incorporated

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) resulting from allegations that Vertex Pharmaceuticals may have issued materially misleading business information to the investing public.

If you purchased Vertex Pharmaceuticals securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Vertex Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On May 2, 2022, before trading hours, Vertex Pharmaceuticals issued a press release providing an update on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. Specifically, the press release revealed that “the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product.”

On this news, Vertex Pharmaceuticals’ stock price fell $11.26 per share, or 4%, to close at $261.96 per share on May 2, 2022.

公司名称: Vertex Pharmaceuticals Incorporated
股票代号: VRTX
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。